Turkey is a USD 3.3 to 4.5 billion medical device market with structural import dependence above 75%, a hospital network of 1,566 facilities, near-universal insurance coverage, and regulatory alignment with the EU. On paper, it looks like one of the more accessible growth markets in the EMEA region for European MedTech companies. In practice, it is one of the more demanding.
The gap between the two is where most market entry strategies go wrong. This article is built to close that gap.
Market Size and Growth: Anchoring on the Right Baseline
Why Three Institutions Publish Three Different Numbers
The first challenge with Türkiye’s medical device market is the data itself. Three credible institutional sources publish three different market size figures for 2024:
- USD 3.3 billion: TİTCK Industry Report and U.S. Commercial Service Country Guide (narrower scope: devices flowing through ÜTS, the national registry)
- USD 4.5 billion: Invest in Türkiye (broader life-sciences definition)
- USD 5.1 billion: Statista MedTech Outlook (MedTech-plus envelope, includes adjacent categories)
None of them is wrong. They measure different things. For a European exporter sizing an opportunity, the right anchor is the institutional baseline of USD 3.3 to 4.5 billion. Anything above that needs to be tested against your specific product category and HS codes before it enters a board presentation.
Growth Rate in Context
The consensus projects 5 to 6% CAGR in USD terms through 2029, consistent with Statista’s 5.26% CAGR estimate. This sits against a backdrop of structural inflation (TÜİK CPI was 47.09% YoY in November 2024 and 31.1% in November 2025) and continued lira depreciation (USD/TRY moved from 35.34 in January 2025 to 42.96 by year-end). Volume growth is real. Margin sustainability in Turkish lira is not guaranteed. The two things are not in contradiction.
Sub-Segment Breakdown
Understanding which categories are growing and why matters more than the headline figure.
| Segment | Market share | Key dynamic |
|---|---|---|
| Consumables | 26% | Volume-driven; price pressure from local and Chinese supply |
| Diagnostic imaging | 18% | Premium-dominated; major refresh cycles ahead |
| Patient aids (hearing, respiratory, cardiac) | 10% | Demographics-driven |
| Orthopaedics and prosthetics | 9% | 80%+ imported; SUT-sensitive pricing |
| Cardiovascular | 8% | Largest single device category (~USD 830 million) |
| Dental supplies | 8% | Medical tourism demand uplift |
| Other (IVD, surgical, ICU, infection control) | 21% | Where most European specialty SMEs find their niche |
Real growth concentrates in advanced diagnostics, dental, robotics, dermatology, and digital health. The headline number hides the niche.
Why the Demand Fundamentals Are Genuinely Strong
Demographics and Disease Burden
The demand case for Türkiye is demographic arithmetic, not market optimism.
Population 85.4 million, with a 65-plus cohort that reached 10.6% in 2024 and is projected to reach 16% by 2040 (OECD Health at a Glance 2025). Obesity at 28.8% versus an OECD average of 25.7%. Over 10 million diabetics. Smoking prevalence at 28%. This is the disease profile that, in mature markets, generates sustained demand for advanced diagnostics, cardiovascular devices, orthopaedic implants, wound care, and home monitoring.
Hospital Infrastructure by the Numbers
The physical infrastructure behind that demand is substantial, per Ministry of Health statistics cited in the U.S. Commercial Service guide:
- 1,566 hospitals (60% public, 36% private, 4% university)
- 267,000 beds, including 49,000 ICU beds
- 1,001 MRI scanners, 1,359 CT scanners, 169 PET scanners, 269 radiotherapy systems
- 39,000 dental units, 1,050 private laboratories
- 164 public hospitals at HIMSS EMRAM Stage 6 or above, with one at Stage 7
The City Hospitals Programme: The Demand Event Most Analyses Miss
The City Hospitals programme represents the single largest healthcare infrastructure modernisation project in Türkiye’s history. 25 city hospitals are now operational across 21 provinces, with approximately 37,000 beds. Fourteen more are under construction, adding around 18,000 beds by 2027 to 2028.
Anchor sites include Ankara Bilkent (3,704 beds, 131 operating rooms, EUR 890 million financing), Ankara Etlik (~3,724 beds, opened 2024), and Başakşehir Çam ve Sakura in Istanbul (USD 1.5 billion, Sojitz/Rönesans consortium). Each of these facilities procures imaging, ICU, surgical robotics, cath-labs, and laboratory automation in 8-figure USD packages. These are not routine tender cycles.
Health Spending and Medical Tourism
Total health expenditure reached USD 42.2 billion in 2023, up 30% year-on-year, with 77.5% public financing and universal insurance coverage through SGK for around 95% of the population (TÜİK 2024).
Medical tourism adds approximately 1.5 to 2 million international patients per year, generating USD 3 billion in direct healthcare revenue per Invest in Türkiye. Dental, hair transplant, aesthetic surgery, ophthalmology, fertility, and oncology lead the inbound flow, creating direct demand for premium equipment in private hospital groups.
The Import Structure: Who Is Actually Winning the Market
Overall Import Dependence
Türkiye imports roughly 75% of its medical devices by value. Import dependence reaches 90 to 95% in advanced imaging, above 85% in cardiovascular implants, above 80% in orthopaedics, and around 80% in consumables. These ratios are not closing within a five-year horizon. Local production sits in lower-technology categories.
Origin Map by Category
Looking at UN Comtrade 2023 data on the major HS lines: for HS 901890 (medical instruments, USD 584 million in Turkish imports), the United States, China, and Germany combined hold 62% of value. China shipped USD 118 million, ahead of Germany at USD 99 million. For CT scanners (HS 902212, USD 63 million), Japan leads at 35%, ahead of the United States at 29% and Germany at 18%.
| Origin | Approximate share | Category strength |
|---|---|---|
| Germany | 17 to 20% | Imaging, IVD, surgical, sterilisation, dental |
| United States | 16 to 19% | Cardiology, robotics, orthopaedics, oncology |
| China | 10 to 14% | Mid-market imaging, ultrasound, monitors, consumables |
| Italy | 6 to 8% | Hospital furniture, dental, dialysis |
| Japan | 6 to 8% | Imaging, endoscopy, IVD, ultrasound |
| France | 4 to 6% | Diagnostics, dental, dialysis, wound care |
| South Korea | 3 to 5% | Aesthetics, dermatology, dental, IVF |
| Switzerland, UK, Netherlands | 7 to 12% combined | Premium niche: cardiology, IVD, dental, hearing |
Three Competitive Patterns That Matter
Germany sets the European benchmark but does not own the market. French, Italian, Dutch, Swiss, and UK exporters compete on equal regulatory and duty terms under the Customs Union. Market share is available for any well-positioned EU SME that executes locally.
China is the structural disruptor. Chinese share has grown faster than any other origin over the past three years. In segments where SGK caps and tender pricing compress margins, Chinese product has become the price benchmark. Europe wins on clinical evidence, service network, installed-base trust, and IFU compliance. Europe loses on price. The competitive response is not matching Chinese pricing. It is building arguments that make Chinese pricing irrelevant to the buyer.
Korean brands are moving faster than acknowledged. In aesthetics, dermatology, dental, and IVF equipment, Korean entrants are gaining share rapidly. The mechanism is familiar to anyone who watched K-beauty: social media and e-commerce adoption first, distribution second. It is beginning to play out in MedTech.
The Regulatory Gate: EU Origin Is a Structural Advantage
Türkiye’s Alignment with EU MDR and IVDR
Türkiye has transposed EU MDR 2017/745 and IVDR 2017/746 with near-verbatim fidelity, and mirrors subsequent EU regulation within 6 to 12 months. CE certificates from EU notified bodies are accepted. The seven Turkish notified bodies issue certificates reciprocally accepted in the EU.
This creates a registration speed advantage of 6 to 9 months for EU-origin devices over Korean, Chinese, US, or Japanese competitors of comparable size. That gap is the asset. It is wasted if the Turkish economic operator and SGK SUT pathway are not started simultaneously.
A Common Misconception Corrected
One claim circulates frequently in market-entry literature that needs correcting. EU-based manufacturers are not required to designate a local authorised representative in Türkiye. The European Commission’s March 2022 Notice to Stakeholders on the EU-Türkiye Customs Union Agreement confirms this explicitly. What EU manufacturers do need is a Turkish-established economic operator authorised by the Ministry of Health as a “medical device sales centre” to register on ÜTS and to sell. This is a commercial and operational requirement. It is not an AR designation in the legal sense. The distinction shapes the distributor contract structure.
Key Regulatory Requirements
Registration happens on ÜTS (Ürün Takip Sistemi), the national device registry with 517,944 products currently listed. Core requirements:
- Pre-market notification via ÜTS (no registration fee)
- Turkish-established economic operator authorised as a medical device sales centre
- Turkish-language IFU and labelling
- Technical file aligned with MDR class requirements, ISO 13485:2016, Declaration of Conformity, GTIN/UDI
- From January 2025: only certified responsible managers may file ÜTS registrations
- E-invoicing with GTIN, batch number and serialisation: effective October 2025 for distributors, October 2026 for pharmacies
Realistic Timeline to First Revenue
| Step | Duration |
|---|---|
| Contracting Turkish economic operator | 6 to 10 weeks |
| Turkish IFU and labelling | 4 to 6 weeks |
| ÜTS dossier preparation | 4 to 8 weeks |
| TİTCK/ÜTS review | 3 to 6 months |
| SGK SUT code matching (run in parallel) | 3 to 6 months |
| First tender or hospital sale | 6 to 12 weeks post-registration |
| Total to first commercial revenue | 9 to 14 months |
Class I and IIa devices sold to private chains without reimbursement targeting can compress to 6 to 12 months. Class III with full SGK inclusion: 18 to 30 months.
The Commercial Gate: Where Most European Entries Actually Stall
SGK Reimbursement and SUT Mechanics
SGK (Sosyal Güvenlik Kurumu) is the single public payer covering ~95% of the population. The SUT (Sağlık Uygulama Tebliği) specifies which device codes are reimbursed and at what tariffs. Without a SUT code and a barcode match between the code and your device’s UDI in SGK’s Medula system, the device cannot be reimbursed by public hospitals. Period.
SUT listing takes 6 to 18 months for established categories and 12 to 24 months for novel devices. SGK uses reference pricing against an EU country basket with a fixed Euro reference rate, adjusted periodically. When lira depreciation outpaces the adjustment cadence, real margins compress without any change in list price. The SUT was updated in May 2024 and again in January 2026, with new codes added across cardiology, gastroenterology, orthopaedics, spine, and dental procedures.
DMO Sağlık Market and Public Tenders
The State Supply Office (DMO) runs Sağlık Market, a centralised procurement platform covering approximately 62% of medical supplies and 93% of pharmaceuticals procured by the Ministry of Health and university hospitals. Standard DMO payment terms are 90 days.
Outside DMO, public hospital days-sales-outstanding averages 16 months and can reach 36 months for university hospitals, per industry association data. This is the largest single working capital risk for new market entrants. Most European exporters discover it when their distributor’s balance sheet starts straining, not before.
Public tenders via the EKAP platform are scored heavily on price. Domestic-content products (holding Yerli Malı certification) receive a preference of up to 15%, a direct output of the 12th Development Plan localisation agenda.
Private Hospital Procurement
This is where premium European devices win most consistently. Acıbadem (29 hospitals, 90% owned by IHH Healthcare), MLP Care (37 facilities across Medical Park and Liv brands), Memorial (12 hospitals), Medicana, Florence Nightingale, and Anadolu Medical Center (Johns Hopkins affiliate) buy on clinical preference, training and service responsiveness, financing terms, and brand positioning aligned with their international patient promise. Cycles are shorter, list prices higher, cash flow cleaner.
Why National Exclusivity Is the Wrong Starting Point
The default European reflex is to appoint one strong national distributor on an exclusive basis. This is the most common avoidable mistake. No single Turkish distributor covers public tenders, university hospitals, large private chains, and provincial markets with equal competence. The distributor that wins DMO tenders is typically not the one with relationships at Acıbadem head office.
National exclusivity also misprices currency risk: when the lira moves 20% in a year, the distributor either passes the risk back, raises prices and loses tenders, or quietly deprioritises the line. Without competitive tension, registration timelines drift.
The working pattern: a specialist tender distributor (often Ankara-based) for public; a direct presence or specialist partner for private chains; regional distributors for provincial and dental markets.
Structural Challenges: The Honest Assessment
Currency Exposure Is Permanent, Not Cyclical
Every imported device, component, and capital equipment item is priced in hard currency. Foreign brands that price commercial agreements in TRY absorb the full FX risk. Hard-currency pricing with transparent quarterly adjustment mechanisms is non-negotiable from day one. Turkish distributors are accustomed to it; it is the market standard.
The Localisation Push Is Real
The 12th Development Plan names medical devices as a priority sector. Domestic-content products receive up to 15% price preference in public tenders. The HIT-30 programme, announced July 2024, commits USD 30 billion across strategic sectors including smart medical devices. Koç Holding’s July 2023 acquisition of Bıçakcılar (consumables, electro-medical, 800 employees) and Anatolia Geneworks’ IVDR certification in May 2024 (the first Turkish manufacturer to achieve this) are signals of how seriously the industrial consolidation is being pursued. The Turkish industry will not displace high-end imports within a five-year horizon, but it is gaining ground in mid-tech.
Three-Layer Competition Is Compressing the Middle
Premium foreign incumbents (Siemens Healthineers, GE HealthCare, Philips, Roche, Medtronic) hold the top. Local manufacturers and Chinese imports set the floor and are moving up the value chain. European mid-market SMEs occupy the squeezed layer. The competitive response is not pricing down. It is depth: clinical evidence, training capacity, service responsiveness, and faster regulatory adaptation than the competition.
Where the Real Opportunities Are
Premium Imaging and Advanced IVD
Import dependence above 90% in advanced imaging. City hospital refresh cycles generate procurement events of scale. Private chains are continuously upgrading: Acıbadem Kartal opened a 127-bed proton therapy and robotic surgery facility in February 2025. SGK now reimburses multi-gene oncology panels and NGS-based prenatal screening. Service-contract economics are as important as equipment sales.
Cardiovascular and Orthopaedic Implants
Cardiology is the largest single device category at around USD 830 million. Orthopaedics imports above 80%. The January 2026 SUT update clarified approval pathways for high-risk implants. KOL-driven adoption in private chains and university hospitals is the commercial entry point.
Dental, Aesthetic and Dermatology
39,000 dental units and a concentrated medical tourism flow. Korean entrants are competing aggressively. European premium implant systems with digital workflow integration and regenerative capability have a defensible positioning, particularly in Istanbul, Ankara, and Antalya.
Premium Consumables and Wound Care
Local and Chinese manufacturers set a low price floor. Advanced wound care, NPWT, antimicrobial systems, and premium sterilisation equipment sit above that floor with an evidence-based argument. SUT listing where reimbursement applies is the commercial priority.
Digital Health and AI Imaging
164 HIMSS EMRAM Stage 6 hospitals and a national teleradiology platform (TELETIP) connecting hundreds of facilities. SaMD registration on ÜTS is straightforward for MDR or IVDR-aligned software. The commercial caveat: SGK does not yet reimburse remote care, limiting scaling for standalone telemedicine products.
OEM and Nearshoring
For European MedTech mid-caps managing MDR transition costs and Chinese supply risk, Türkiye is a credible nearshoring base. The Customs Union eliminates EU import tariffs. Turkish notified body certificates are accepted in the EU. The cost base is 30 to 50% below Western Europe. Manufacturers in Tekirdağ, Bursa, Konya, OSTİM, and İkitelli have available capacity in injection moulding, packaging, sterilisation, and assembly.
Three Conditions for a Viable Market Position
Hard-Currency Pricing
Commercial agreements in TRY transfer the full FX risk to the European manufacturer. Hard-currency pricing with transparent adjustment mechanisms is non-negotiable and expected by Turkish distributors.
Parallel Workstreams
Registration, SUT listing, economic operator setup, and channel design must run simultaneously from week one. Sequential phasing is the most common reason European entrants arrive at their first tender cycle without reimbursement coverage or with a distributor covering the wrong channel.
Channel Segmentation
Public tender, university hospitals, large private chains, and provincial markets are four distinct commercial environments requiring different distributor profiles. National exclusivity is an administrative shortcut that costs the second year.
Final Assessment
Türkiye’s medical device market rewards those who approach it as a structural project. The demand is there. The regulatory framework is aligned. The procurement infrastructure, however demanding, is navigable. What it requires is the right preparation, the right partners, and the discipline to run regulatory and commercial workstreams in parallel rather than in sequence.
If you are evaluating entry or reviewing an existing position in the Turkish market, reach out to discuss what it actually requires for your product class.
Frequently Asked Questions
What is the size of the medical device market in Türkiye?
The Turkish medical device market is valued between USD 3.3 and 4.5 billion in 2024, depending on the scope used. The TİTCK Industry Report and U.S. Commercial Service anchor the figure at USD 3.3 billion for devices flowing through the national ÜTS registry. Invest in Türkiye publishes USD 4.5 billion using a broader life-sciences definition. For market entry sizing, we recommend the institutional range of USD 3.3 to 4.5 billion as the operational baseline.
Do EU medical device manufacturers need a local authorised representative in Türkiye?
No. Under the EU-Türkiye Customs Union Agreement, EU-based manufacturers are exempt from appointing a Turkish authorised representative. The European Commission confirmed this in its March 2022 Notice to Stakeholders. What EU manufacturers do need is a Turkish-established economic operator authorised by the Ministry of Health as a medical device sales centre to register on ÜTS and to sell in market. This is not the same as an AR in the legal sense, and the distinction shapes how distribution and registration contracts should be structured.
How long does medical device registration take in Türkiye?
For a Class IIb device from a CE-certified EU manufacturer with a competent local economic operator, the realistic timeline to first commercial revenue is 9 to 14 months, with regulatory and SGK SUT workstreams running in parallel. Class I and IIa devices sold to private chains without reimbursement targeting can reach first revenue in 6 to 12 months. Class III devices requiring full SGK SUT inclusion should budget 18 to 30 months.
How does SGK reimbursement work for medical devices?
SGK (Sosyal Güvenlik Kurumu) is the single public payer covering around 95% of the Turkish population. The SUT (Sağlık Uygulama Tebliği) is the reimbursement rulebook, specifying which device codes are covered and at what tariffs. Without a SUT code and a barcode match between the code and your device’s UDI in SGK’s Medula system, the device cannot be reimbursed in public hospitals. SUT listing typically takes 6 to 18 months for established categories. SGK uses reference pricing against an EU country basket via a fixed Euro rate adjusted periodically, not continuously.
What are the main challenges for European MedTech companies entering the Turkish market?
The four structural challenges are: currency exposure (the lira depreciated approximately 78% against the USD between 2021 and 2025, and SGK reimbursement adjustments lag depreciation); public hospital payment terms (DMO standard is 90 days, but broader public hospital DSO averages 16 months and can reach 36 months for university hospitals); three-layer competitive pressure (premium foreign incumbents above, local and Chinese suppliers below, European mid-market squeezed in the middle); and the localisation push under the 12th Development Plan, which includes domestic-content price preferences of up to 15% in public tenders.
Is a single national distributor sufficient for the Turkish market?
Generally, no. Public tender and DMO procurement, university hospital supply, large private chain procurement, and provincial private and dental markets are four distinct commercial environments. No single Turkish distributor covers all four with equal competence or relationships. National exclusivity also concentrates currency risk in one counterparty. The working pattern we recommend is channel-segmented: a specialist tender distributor for public procurement, a direct presence or dedicated partner for large private chains, and regional distributors for provincial and dental markets.